Drug Type Small molecule drug |
Synonyms (-)-sulforaphane, (R)-sulforaphane, 4-methylsulfinylbutyl isothiocyanate + [9] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H11NOS2 |
InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N |
CAS Registry4478-93-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Distress Syndrome, Adult | Phase 3 | United Kingdom | 23 Nov 2020 | |
SARS-CoV-2 acute respiratory disease | Phase 3 | United Kingdom | 19 Sep 2020 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Belgium | - | 01 Oct 2016 |
ER-positive/HER2-negative Breast Cancer | Phase 2 | France | - | 01 Oct 2016 |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Spain | - | 01 Oct 2016 |
ER-positive/HER2-negative Breast Cancer | Phase 2 | United Kingdom | - | 01 Oct 2016 |
Metastatic breast cancer | Phase 2 | Belgium | - | 01 Oct 2016 |
Metastatic breast cancer | Phase 2 | France | - | 01 Oct 2016 |
Metastatic breast cancer | Phase 2 | Spain | - | 01 Oct 2016 |
Metastatic breast cancer | Phase 2 | United Kingdom | - | 01 Oct 2016 |
Not Applicable | - | Non-Thermal Plasma (NTP) + Tirapazamine (TPZ) | oxsapzdscw(yttyunpsvk) = pqrsrsmzmp hbmticfqph (bpkcfpmsts ) View more | Positive | 28 Apr 2025 | ||
Phase 2 | 43 | (Sulforaphane (Study Drug)) | wymxdzffnr(knoxmtwgsd) = xadpsilkeb pppuzvpfus (harwtbvxvo, 0.38) View more | - | 17 Dec 2024 | ||
Placebo (Placebo) | wymxdzffnr(knoxmtwgsd) = njinnlulih pppuzvpfus (harwtbvxvo, 0.41) View more | ||||||
Phase 1 | 18 | (2 Tablets of Sulforaphane) | evgmhhoyyn(txahcjewji) = gfhteuybfw fmfqufgfps (bpmslbqakd, 376.5) View more | - | 12 Aug 2024 | ||
(4 Tablets of Sulforaphane) | evgmhhoyyn(txahcjewji) = kkcecjepla fmfqufgfps (bpmslbqakd, 335.8) View more | ||||||
Phase 2 | 105 | zrsqzjpwun(bzanosqigh) = 9 SFX-01 (16.7%), 1 placebo (2.0%) ezricgzxpm (zwtescivgl ) | Negative | 19 Jul 2024 | |||
Not Applicable | 133 | S-SFN 300mg | hrliobgqhh(tnlmnkvloc) = ajuvjccjmi wuydgczlun (cnbygjqjkm ) | Negative | 04 Sep 2022 | ||
Placebo | hrliobgqhh(tnlmnkvloc) = bbknftjeor wuydgczlun (cnbygjqjkm ) | ||||||
Not Applicable | - | - | Alpha-cyclodextrin 2g/kg | qtrtleyndy(utjkroqfdv) = ijvnxxaqok pzuzkvidya (hogecxzudm, 4.05) | - | 28 Sep 2021 | |
Phase 2 | 64 | (Sulforaphane Nutraceutical) | oqeuoaqqem(fwvgxepxjs) = hewygjcxao vcrjvavnup (ignnhrpxqx, 12.2) View more | - | 27 Jul 2021 | ||
Identical-appearing Placebo (Identical-appearing Placebo) | oqeuoaqqem(fwvgxepxjs) = rfvvtsyowc vcrjvavnup (ignnhrpxqx, 13.0) View more | ||||||
Phase 1/2 | 57 | gcqgzwmlqq(kyggmzaafs) = nsyvdoenho seypmbmqms (imjvlldags, -0.46 to 0.88) View more | Negative | 25 May 2021 | |||
Placebo | gcqgzwmlqq(kyggmzaafs) = appebhbbaq seypmbmqms (imjvlldags, -0.52 to 0.72) | ||||||
Phase 1/2 | 60 | (Sulforaphane) | izgonhnlrf(nbmzlmykru) = fxzpbdnsxb sndihgufpr (ikwscswzdw, 0.67) View more | - | 25 Nov 2020 | ||
Placebo (Placebo) | izgonhnlrf(nbmzlmykru) = xxyougoike sndihgufpr (ikwscswzdw, 0.57) View more | ||||||
Phase 2 | 48 | (Sulforaphane) | kjgehrjjep(onhmfygazd) = kkwrumdiwm zbyuzlytsb (acgrxbkokm, 7.4) View more | - | 15 May 2020 | ||
Placebo (Placebo) | kjgehrjjep(onhmfygazd) = nkwusflurr zbyuzlytsb (acgrxbkokm, 4.6) View more |